Daniel Clark analyst LEERINK

Currently out of the existing stock ratings of Daniel Clark, 16 are a BUY (72.73%), 6 are a HOLD (27.27%).

Daniel Clark

Work Performance Price Targets & Ratings Chart

Analyst Daniel Clark, currently employed at LEERINK, has had 40% of price targets met with an average potential upside of 9.4%, reached in 43 days on average.

Daniel Clark has documented 43 price targets and ratings displayed on 5 stocks. The coverage is on the Healthcare sector.

Most recent stock forecast was given on VTRS, Viatris.

Wall Street Analyst Daniel Clark

Analyst best performing recommendations are on IDXX (IDEXX LABORATORIES).
The best stock recommendation documented was for IDXX (IDEXX LABORATORIES) on 7/17/2025. The price target of $600 was fulfilled within 18 days with a profit of $81.29 (15.67%), with a performance score of 8.71.

Average potential price target upside

ELAN Elanco Animal Health IDXX IDEXX Laboratories ZTS Zoetis VTRS Viatris AMRX Amneal Pharmaceuticals

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date of last PT

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score

Buy Since 18-Dec-2023

$32

$6.26 (24.32%)

$30

3 days ago
(19-Nov-2026)

Hold Since 29-Jan-2025

$25

$-0.74 (-2.87%)

$26

24 days ago
(29-Oct-2026)

15/20 (75%)

$1.76 (7.57%)

249

Buy Since 07-May-2026

$24

$-1.74 (-6.76%)

$30

1 months 2 days ago
(20-Oct-2026)

1/2 (50%)

$1.3 (5.73%)

13

Buy Since 21-Nov-2025

$30

$4.26 (16.55%)

$29

3 months 16 days ago
(06-Aug-2026)

0/3 (0%)

$5.8 (23.97%)

Buy Since 09-Dec-2024

$33

$7.26 (28.21%)

$30

3 months 16 days ago
(06-Aug-2026)

5/8 (62.5%)

$8.8 (36.36%)

115

Show more analysts

Please expand the browser size to see the chart

Which stock is Daniel Clark most bullish on?

Potential upside of $4.37 has been obtained for VTRS (VIATRIS)

Which stock is Daniel Clark most reserved on?

Potential downside of $3.88 has been obtained for AMRX (AMNEAL PHARMACEUTICALS)

What Year was the first public recommendation made by Daniel Clark?

On 2024
✖

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?